Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Significant Growth in Short Interest

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 8,480,000 shares, an increase of 18.6% from the February 29th total of 7,150,000 shares. Based on an average daily trading volume, of 941,700 shares, the days-to-cover ratio is presently 9.0 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Atossa Therapeutics during the 3rd quarter worth approximately $98,000. GSA Capital Partners LLP boosted its stake in shares of Atossa Therapeutics by 29.3% during the 4th quarter. GSA Capital Partners LLP now owns 449,082 shares of the company's stock worth $395,000 after acquiring an additional 101,690 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Atossa Therapeutics by 4.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 313,912 shares of the company's stock valued at $393,000 after purchasing an additional 14,481 shares during the period. Bank of Montreal Can bought a new stake in Atossa Therapeutics in the 2nd quarter valued at $365,000. Finally, Northern Trust Corp boosted its stake in Atossa Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 227,922 shares of the company's stock valued at $201,000 after purchasing an additional 13,280 shares during the period. 12.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on ATOS. HC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Atossa Therapeutics in a report on Monday, February 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Atossa Therapeutics in a report on Friday, January 12th. Finally, StockNews.com cut Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Monday, March 18th.

Atossa Therapeutics Trading Down 1.6 %

Shares of NASDAQ:ATOS traded down $0.03 during trading on Friday, hitting $1.80. 1,890,373 shares of the company were exchanged, compared to its average volume of 2,119,995. The stock has a market cap of $225.54 million, a price-to-earnings ratio of -7.50 and a beta of 1.16. Atossa Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $1.94. The firm has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $0.89.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.